Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio
Incyte will present data from across its Inflammation and Autoimmunity portfolio at the European Academy of Dermatology and Venereology (EADV) 2026 congress in Vienna, September 30 - October 3, with one oral presentation in atopic dermatitis and more than a dozen posters. The slate is anchored by ruxolitinib cream (Opzelura) long-term and real-world studies in atopic dermatitis and vitiligo, including 24-week TRuE-AD4 safety and patient-reported outcomes, plus pooled Phase 3 STOP-HS1/STOP-HS2 results for povorcitinib in moderate-to-severe hidradenitis suppurativa.
Key figures
- Eadv congress dates
- September 30 - October 3, 2026, Vienna, Austria
- Opzelura patients treated
- more than one million patients globally
- Povorcitinib regulatory status
- HS NDA under FDA review and MAA under EMA review
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.